Psychemedics Corporation
PMD

$13.79 M
Marketcap
$2.34
Share price
Country
$0.00
Change (1 day)
$3.93
Year High
$1.63
Year Low

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

marketcap

P/B ratio for Psychemedics Corporation (PMD)

P/B ratio as of 2023: 2.55

According to Psychemedics Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.55. At the end of 2022 the company had a P/B ratio of 2.56.

P/B ratio history for Psychemedics Corporation from 1988 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 2.55
2022 2.56
2021 3.18
2020 2.25
2019 3.00
2018 4.66
2017 6.06
2016 8.61
2015 4.69
2014 6.32
2013 6.34
2012 5.04
2011 4.31
2010 4.38
2009 4.11
2008 3.19
2007 6.02
2006 8.65
2005 8.00
2004 10.65
2003 9.52
2002 7.73
2001 12.80
2000 12.53
1999 9.25
1998 7.16
1997 7.89
1996 9.30
1995 13.75
1994 6.86
1993 8.86
1992 17.33
1991 13.74
1990 16.66
1989 65.74
1988 2.97